RecruitingPhase 2NCT05960773
Oncology
Malignant Pleural Mesothelioma
Also known as MPM, asbestos-related mesothelioma, peritoneal mesothelioma, BAP1 tumor
Malignant pleural mesothelioma is an aggressive, diffuse malignancy of the pleural mesothelium most strongly causally associated with prior asbestos exposure, with a latency period of 20–50 years. Loss-of-function mutations in BAP1 (BRCA1-a
ORPHA:50251 ↗Gene BAP1Gene NF2Prevalence 1–2 in 100,000Onset Adult (median age 70s; long latency of 30–50 years from asbestos exposure)Sporadic (asbestos-related); BAP1 tumour predisposition syndrome in familial cases
50
studies recruiting now
as of 7 Sept 2026
386
studies registered in total
as of 7 Sept 2026
7
countries with a recruiting site
as of 7 Sept 2026
9 Feb 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT04981119
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingPhase 1NCT06251310
SW-682 in Advanced Solid Tumors
RecruitingNCT00242723
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
RecruitingPhase 1 / Phase 2NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 50 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Malignant Pleural Mesothelioma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: MARF Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Malignant Pleural Mesothelioma
Malignant pleural mesothelioma is an aggressive, diffuse malignancy of the pleural mesothelium most strongly causally associated with prior asbestos exposure, with a latency period of 20–50 years. Loss-of-function mutations in BAP1 (BRCA1-associated protein 1), a nuclear deubiquitinase and tumour suppressor, and NF2 (merlin) are the most common somatic genetic alterations, with germline BAP1 mutations conferring the BAP1 tumour predisposition syndrome. The combination of nivolumab and ipilimumab (dual checkpoint blockade) has become a new first-line standard in non-epithelioid histology, but outcomes remain poor with median overall survival of 12–18 months for all comers.
Common clinical features
Progressive dyspnoea from pleural effusion or direct pleural encasement of the lungChest pain: dull, constant, often pleuritic, worsening with inspirationUnexplained weight loss, cachexia, and fatigueRestricted chest expansion and decreased breath sounds on the affected sidePhrenic nerve palsy causing paradoxical diaphragmatic movementSuperior vena cava obstruction in advanced disease with mediastinal involvementPeritoneal extension causing ascites and abdominal distension in advanced cases
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 28 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pemetrexed (Alimta)
Phase 3Vinorelbine
Phase 3Ipilimumab (Yervoy)
Phase 3Pembrolizumab (Keytruda)
Phase 3Durvalumab (Imfinzi)
Phase 3Nivolumab (Nivolumab bms)
Phase 3Gemcitabine (Gemzar)
Phase 2Cisplatin (Cisplatin)
Phase 2Carboplatin (Carboplatin)
+ 20 more in development
Before you apply
Things trial teams commonly ask about for Malignant Pleural Mesothelioma. Not eligibility rules; those are set by each study.
- Histological subtype (epithelioid, sarcomatoid, or biphasic) must be confirmed on adequate tissue, as it is a primary eligibility and stratification criterion — fine needle aspirate alone is typically insufficient for trial entry.
- Asbestos exposure history (occupational, domestic, or environmental) and documentation of latency period are required for certain aetiologically defined trials and for compensation-linked registry enrolment.
- BAP1 IHC loss or germline BAP1 testing is increasingly requested for biomarker-selected trials and for BAP1 tumour predisposition syndrome family screening; arrange germline testing if tumour shows BAP1 loss.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).